RCC market focus AVEO markets FOTIVDA for relapsed or refractory renal cell carcinoma and is pursuing immuno-oncology combinations and other indications, signaling ongoing revenue potential beyond current approvals.

ASCO presence Active participation and poster presentations at major conferences (ASCO 2026) create opportunities to engage key oncologists, potential partners, and KOLs for investigator-sponsored trials and co-development discussions.

Strategic partnership Existing collaboration with LG Chem and prior partnerships (NiKang Therapeutics) indicate openness to licensing, co-development, and strategic alliances to accelerate late-stage trials and geographical expansion.

Clinical leadership New Chief Medical Officer appointed in 2024 enhances clinical oversight, enabling more robust clinical programs, trial designs, and credible conversations with sponsors and payers.

Financial and people Revenue scale and substantial funding, combined with recognized workplace quality, suggest capacity for expanded commercial activities, potential for value-add partnerships, and attraction of strategic investors.